Repros Therapeutics Inc. (RPRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
RPRX POWR Grades
- Stability is the dimension where RPRX ranks best; there it ranks ahead of 93.09% of US stocks.
- The strongest trend for RPRX is in Quality, which has been heading down over the past 179 days.
- RPRX ranks lowest in Momentum; there it ranks in the 8th percentile.
RPRX Stock Summary
- RPRX's went public 1.79 years ago, making it older than merely 4.51% of listed US stocks we're tracking.
- Of note is the ratio of Royalty Pharma plc's sales and general administrative expense to its total operating expenses; merely 8.65% of US stocks have a lower such ratio.
- The volatility of Royalty Pharma plc's share price is greater than that of only 6.07% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Royalty Pharma plc are SSRM, CNHI, PCAR, KGC, and DD.
- To check out Royalty Pharma plc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001802768.
RPRX Valuation Summary
- In comparison to the median Healthcare stock, RPRX's price/sales ratio is 7.49% lower, now standing at 10.5.
- Over the past 15 months, RPRX's price/sales ratio has gone down 4.1.
- Over the past 15 months, RPRX's price/sales ratio has gone down 4.1.
Below are key valuation metrics over time for RPRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RPRX | 2021-08-31 | 10.5 | 2.3 | 24.2 | 25.2 |
| RPRX | 2021-08-30 | 10.6 | 2.3 | 24.4 | 25.4 |
| RPRX | 2021-08-27 | 10.6 | 2.3 | 24.5 | 25.5 |
| RPRX | 2021-08-26 | 10.6 | 2.3 | 24.3 | 25.4 |
| RPRX | 2021-08-25 | 10.6 | 2.3 | 24.4 | 25.5 |
| RPRX | 2021-08-24 | 10.6 | 2.3 | 24.4 | 25.5 |
RPRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RPRX has a Quality Grade of C, ranking ahead of 62.21% of graded US stocks.
- RPRX's asset turnover comes in at 0.139 -- ranking 231st of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows RPRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.139 | 1 | 0.054 |
| 2021-03-31 | 0.138 | 1 | 0.056 |
| 2020-12-31 | 0.139 | 1 | 0.059 |
RPRX Price Target
For more insight on analysts targets of RPRX, see our RPRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $51.43 | Average Broker Recommendation | 1.67 (Moderate Buy) |
RPRX Stock Price Chart Interactive Chart >
RPRX Price/Volume Stats
| Current price | $41.27 | 52-week high | $47.10 |
| Prev. close | $40.01 | 52-week low | $34.86 |
| Day low | $40.21 | Volume | 1,458,900 |
| Day high | $41.45 | Avg. volume | 1,951,277 |
| 50-day MA | $40.69 | Dividend yield | 1.84% |
| 200-day MA | $39.35 | Market Cap | 25.06B |
Latest RPRX News From Around the Web
Below are the latest news stories about Royalty Pharma plc that investors may wish to consider to help them evaluate RPRX as an investment opportunity.
Royalty Pharma Announces Inaugural Investor DayNEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30 a.m. ET. Royalty Pharma senior executives will present on the outlook for royalty funding in life sciences, the company’s capital deployment opportunities and long-term growth targets. The meeting will include live question and answer sessions. Additional details will follow closer to the event. The l |
Royalty Pharma Reports Q4 and Full Year 2021 ResultsNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2021 and introduced 2022 Adjusted Cash Receipts ( 1) (a non-GAAP financial measure) guidance. |
Royalty Pharma reports Q4 resultsRoyalty Pharma press release (RPRX): Q4 consolidated net income of $54M.Revenue of $576M (+0.7% Y/Y) beats by $32.63M.Full Year 2022 guidance: Adjusted Cash Receipts of $2,225 to… |
Royalty Pharma plc (RPRX) Q4 2021 Earnings Call TranscriptRPRX earnings call for the period ending December 31, 2021. |
Royalty Pharma Q4 2021 Earnings PreviewRoyalty Pharma (NASDAQ:RPRX) is scheduled to announce Q4 earnings results on Tuesday, February 15th, before market open.The consensus EPS Estimate is $0.78 and the consensus… |
RPRX Price Returns
| 1-mo | -4.79% |
| 3-mo | 7.78% |
| 6-mo | 0.77% |
| 1-year | 4.72% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 4.54% |
| 2021 | -19.09% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
RPRX Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...